Company Overview of Cellerant Therapeutics, Inc.
Cellerant Therapeutics, Inc., a clinical stage biotechnology company, focuses on the regulation of the hematopoietic (blood-forming) system. It develops human stem cell and antibody therapies for oncology applications and blood-related disorders. The company’s pipeline products include CLT-008, an off-the-shelf cell-based therapy for the treatment of neutropenia associated with chemotherapy in oncology patients, cord blood transplantation, and acute radiation exposure; and a cancer stem cell antibody discovery program focused on therapies for acute myeloid leukemia, multiple myeloma, and myelodysplastic syndrome. Cellerant Therapeutics, Inc. was formerly known as Celtrans, LLC. The company w...
1561 Industrial Road
San Carlos, CA 94070
Founded in 2001
Key Executives for Cellerant Therapeutics, Inc.
Chief Executive Officer, President and Director
Senior Vice President of Regulatory, QA & Project Management
Vice President of Corporate Development
Vice President of Government Operations and Controller
Compensation as of Fiscal Year 2015.
Cellerant Therapeutics, Inc. Key Developments
Cellerant Therapeutics Inc. Appoints Rodney Young as Chief Financial Officer
Jun 16 15
Cellerant Therapeutics Inc. announced that Rodney Young has joined the Company as Chief Financial Officer. Mr. Young brings more than 25 years of financial and executive experience in the life sciences field as a chief financial officer and investment banker. Mr. Young comes to Cellerant with significant corporate finance and leadership experience. Mr. Young was previously Chief Financial Officer at StemCells, Inc.
Cellerant Announces Dosing of First Patient in Randomized Phase 2 Clinical Trial of CLT-008 in Acute Myeloid Leukemia Patients
Mar 17 15
Cellerant Therapeutics Inc. announced that patient dosing has commenced in its multi-center, open-label, randomized controlled Phase 2 clinical trial of CLT-008, a first-in-class, allogeneic, cellular therapy, in de novo acute myeloid leukemia (AML) patients receiving induction chemotherapy. The Phase 2 trial is expected to enroll up to 140 de novo AML patients 55 years of age, randomized in 1:1 ratio to either Filgrastim alone or CLT-008 single infusion plus Filgrastim. The study will evaluate the effect of CLT-008 on the duration of febrile episodes and infections related to cytarabine-based induction chemotherapy. The primary endpoint will be the duration of febrile episodes from infusion of CLT-008 to day 28. Secondary endpoints will include incidence of infection, duration of antibiotic use, incidence of mucositis, duration of hospitalization, and hematologic recovery. The Phase 2 data will guide the design and choice of endpoints for the pivotal Phase 3 trial. Interim analysis is expected to take place after 50% of the patients are enrolled. Cellerant has treated 75 patients in two Phase 1 dose escalation clinical trials with CLT-008. One trial tested CLT-008 in 45 leukemia patients following induction or consolidation chemotherapy. Several dose levels of CLT-008 were examined with or without Filgrastim. Data from the study show that CLT-008 was safe and well tolerated. Signals of clinical activity were observed with reductions in duration of fever (days in a febrile episode) and in the incidence of WHO Grade 2 mucositis in AML patients receiving induction therapy. Clinical data from this study were presented at the 2014 American Society of Hematology (ASH) Annual Meeting and Exposition in San Francisco on December 7, 2014.
Cellerant to Present Phase 1 Clinical Data on Evaluation of CLT-008 in Patients with Acute Myeloid Leukemia at the 2014 American Society of Hematology Annual Meeting
Dec 5 14
Cellerant Therapeutics Inc. announced that data from the Phase 1 clinical trial for CLT-008, a first-in-class, allogeneic, cell-based therapy for use in patients with acute myeloid leukemia (AML), will be presented at the 2014 American Society of Hematology (ASH) Annual Meeting and Exposition in San Francisco, December 6-9, 2014. Based on these positive Phase 1 results, Cellerant is initiating a multi-center, prospective, randomized Phase 2 clinical trial to demonstrate a decrease in risks of febrile episodes and infections related to chemotherapy treatment in AML. If successful, CLT-008 may also be applicable in many other clinical settings where chemotherapy-induced severe neutropenia is present.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|